Home > PJ (current issue) > Onlooker | Search

Return to PJ Online Home Page

The Pharmaceutical Journal
Vol 271 No 7265 p304
6 September 2003

This article
Reprint
Photocopy

   

PDF* 75K

Onlooker

Antibiotic sense [more]
Yellow bane [more]
Losing talent [more]


Antibiotic sense

We have known for decades that routine feeding of antibiotics to livestock intended for human consumption is one of the ways in which micro-organisms develop resistance to antimicrobial therapy. Nevertheless, we have done little about it because of the power of the vested interests which find antibiotic supplementation commercially advantageous. Unfortunately this habit enables food producers to speed production by increasing the rate of growth of their livestock. This must be regarded as a foolish and short-sighted policy.

The attitude is gradually changing. According to a report published in Science for 22 August, the World Health Organization has recently published a statement to the effect that eliminating the routine antibiotic treatment of stock can reduce the hazard to humans of induced resistance of micro-organisms to any necessary therapy without significantly threatening the health of livestock or the income of farmers. And the European Union has ordered member countries to cease the controversial practice by the year 2006.

The bulk of the evidence on which WHO came to a decision has come from Denmark, which has now eliminated the practice. The WHO co-ordinator on food-borne diseases has commented: “Under conditions similar to those in Denmark, the use of antimicrobials for the sole purpose of growth promotion can be discontinued.”

It is true that low doses of antibiotics make animals grow slightly faster on less feed, presumably by suppressing minor infections that do not produce symptoms of illness. At the same time, some organisms become resistant to the agents employed, and resistant strains may be transferred by way of the meat and find their way into the human gut. There is no rooted objection to treating sick animals with antibiotics to achieve a cure, or to using them to prevent spread of an infection to other animals. But here we reach the limit of justifiable treatment.

In the Danish research on which these conclusions are based, the prevalence of antibiotic-resistant strains of the organisms in farm animals, abattoirs, articles of grocery and healthy consumers was studied over a space of four years. Animal health and farming economics were also noted. Total use of antibiotics in pigs and poultry over the period fell by some 54 per cent, and at the same time there was a significant reduction of resistant strains of organisms such as enterococci. No figures regarding the incidence of resistant strains in consumers were obtained. Farmers suffered a slight economic disadvantage, but at the same time they found a reduction in expenses involved in keeping infection out of barns and hiring additional staff to deal with that problem.

In contrast, in the United States no restrictions have so far been introduced to deal with the problem, although a bill has been introduced into Congress to prevent livestock producers from using penicillins, tetracyclines and six other antibiotics on entire herds until the harmlessness of the procedure has been proven. And one at least of the fast-food chains operating in the US has insisted on a reduction in antibiotic treatment of the chickens it purchases.

Back to Top


Yellow bane

In the August issue of The Countryman is an interesting account by Jo Kirby of an attractive plant that is now prominent in our rough pastures. It grows in the hollows that run along the hedges and provide a moist habitat for it.

The plant is the humble fleabane, Pulicaria dysenterica, once known as Inula dysenterica. The current generic name refers to its ability to repel the flea (pulex), while the specific name has a strange historical origin. It is recorded that Linnaeus coined it after being told by the Russian General Kett that during an expedition against Persia his troops had successfully cured themselves of dysentery by consuming fleabane.

In Arabian regions fleabane had another use. A decoction of the roots was used, it was said, by the patriarch Job to soothe his notorious boils; hence it derived the local name of Job’s tears. Fleabane enjoyed the vernacular name “harvest flower” in Britain country, since it was used to decorate the first product of the autumn harvest.

Fleabane is a perennial which grows to a height of about half a metre, with erect hairy stems and woolly arrow-shaped leaves. The typical composite flower-head is bright yellow, about 3cm broad, the ray florets numerous, long and narrow round a darker disc. The creeping rootstock produces a clumping effect in the field. The leaves have a faint odour reminiscent of chrysanthemum and soap. Bunches were once hung in living rooms to discourage insect pests, or were burnt to fumigate the house.

A decoction has been used in folk medicine to relieve itching of the skin, and the bruised plant has been applied to the forehead of persons suffering from nervous disorders as a calming influence.

Back to Top


Losing talent

A special feature published in The Lancet earlier this summer drew attention to the urgent problem of the brain drain of scientists from Europe to the United States.

A recent study by the European Commission has revealed that 75 per cent of European graduates studying in the US express a preference to remain there after they have completed their doctorate because they see better opportunities for a career and employment as scientists. At the moment about half of those Europeans who complete their studies in the US remain for long periods afterwards, and many choose to remain there permanently. Only about a third of those from the UK return home. Yet three-quarters of the students from Germany do return to their native land to work. Among reasons given for staying in the US were the proliferation of good research centres, flexible and open career structures, a strong entrepreneurial culture and high living standards and quality of life.

European officials claim that such loss of native talent threatens Europe’s economic rivalry with Japan and the US, both of which already spend more than Europe on research and development. Unless careers in Europe are made more attractive to scientists, the flow of talented young graduates will continue to increase. Many who train as scientists in Europe tend to divert into more attractive kinds of work. At the same time, the average age of European scientists is increasing, with one third of these due to retire during the coming decade.

Europe has a capricious system of career advancement, with social connections often more influential than professional talent. Young researchers are often given excessive teaching responsibilities and insufficient opportunity for research and are offered slim chances of promotion. And science graduates in Europe tend to be regarded with suspicion and denied the greater respect that they enjoy in the US.

One remedy might be the establishment of an independent pan-European funding agency for science, concentrating on long-term basic research and not subjected to narrow national interests.

Back to Top


  * PDF files on PJ Online require Acrobat Reader 4 or later


Home | Journals | News | Notice-board | Search | Jobs  Classifieds | Site Map | Contact us

©The Pharmaceutical Journal